BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2013

May 24, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2013-05-22

Reporting Person: FUCHS HENRY J (EVP, Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-05-22	Common Stock	M	10000	$11.05	Acquired	64973	Direct
2013-05-22	Common Stock	S	11899	$65.6559	Disposed	53074	Direct
2013-05-23	Common Stock	S	8710	$67.162	Disposed	44364	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-05-22	Stock Option (right to buy) Common Stock	$11.05	D	10000	Disposed	2019-03-02	Common Stock (10000)	Direct

Footnotes

F1: Transaction made pursuant to 10b5-1 trading plan executed on May 8, 2013

F2: The price in column 4 is weighted average price. The price actually received ranged from $63.32 to $66.23. The reporting person will provide to the isuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: The price in column 4 is weighted average price. The price actually received ranged from $65.51 to $68.05. The reporting person will provide to the isuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4: Option grant vests 6/48ths on September 2, 2009 and 1/48th on the 2nd day of every month thereafter.

F5: Reflects number of stock options outstanding after the transaction from this specific stock option grant.